Nesiritide

Nesiritide

Clinical data
Routes of administration	IV only
ATC code	C01DX19 (WHO)
Identifiers
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C143H244N50O42S4
Molar mass	3464 g/mol

WikiDoc Resources for Nesiritide
Articles
Most recent articles on Nesiritide Most cited articles on Nesiritide Review articles on Nesiritide Articles on Nesiritide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Nesiritide Images of Nesiritide Photos of Nesiritide Podcasts & MP3s on Nesiritide Videos on Nesiritide
Evidence Based Medicine
Cochrane Collaboration on Nesiritide Bandolier on Nesiritide TRIP on Nesiritide
Clinical Trials
Ongoing Trials on Nesiritide at Clinical Trials.gov Trial results on Nesiritide Clinical Trials on Nesiritide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Nesiritide NICE Guidance on Nesiritide NHS PRODIGY Guidance FDA on Nesiritide CDC on Nesiritide
Books
Books on Nesiritide
News
Nesiritide in the news Be alerted to news on Nesiritide News trends on Nesiritide
Commentary
Blogs on Nesiritide
Definitions
Definitions of Nesiritide
Patient Resources / Community
Patient resources on Nesiritide Discussion groups on Nesiritide Patient Handouts on Nesiritide Directions to Hospitals Treating Nesiritide Risk calculators and risk factors for Nesiritide
Healthcare Provider Resources
Symptoms of Nesiritide Causes & Risk Factors for Nesiritide Diagnostic studies for Nesiritide Treatment of Nesiritide
Continuing Medical Education (CME)
CME Programs on Nesiritide
International
Nesiritide en Espanol Nesiritide en Francais
Business
Nesiritide in the Marketplace Patents on Nesiritide
Experimental / Informatics
List of terms related to Nesiritide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Nesiritide (Natrecor®) is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). Nesiritide is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. Nesiritide works to facilitate cardiovascular fluid homeostasis through counterregulation of the renin-angiotensin-aldoesterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation. In simpler terms, it promotes vasodilation, natriuresis, and diuresis.

Administration

Nesiritide is only administered intravenously, usually by bolus, followed by IV infusion. For most adults and the elderly, a normal dosage is 2 micrograms/kilogram followed by a continuous IV infusion of 0.01 mcg/kg/minute. This may be increased every three hours for a maximum of 0.03 mg/kg/min.

Correction - maximum dose is 0.03 MCG/kg/minute, not MG.

Side effects

Common side effects include:

• Low blood pressure (11% of patients)
• Headache
• Nausea
• Slow heart rate

More rare side effects include:

• Confusion
• Paresthesia
• Somnolence
• Tremors

Recommendations for use (as of 7/13/2005)

There have been several meta-analysis which have identified issues of increased mortality and increased renal dysfunction with use of nesiritide compared to usual therapy. As a result, the company which manufactures nesiritide (Scios), consulted with Dr E Braunwald to develop recommendations for use. They are as follows:

• The use of nesiritide should be strictly limited to patients presenting to the hospital with acutely decompensated heart failure who have dyspnea at rest, as were the patients in the largest trial that led to approval of the drug (VMAC). Physicians considering the use of nesiritide should consider its efficacy in reducing dyspnea, the possible risks of the drug (refers to meta-analysis), and the availability of alternate therapies to relieve the symptoms of congestive heart failure.
• Nesiritide should not be used to replace diuretics. Furthermore, because insufficient evidence is not currently available to demonstrate benefit for the applications listed below,

• • NESIRITIDE SHOULD NOT BE USED:
  • for intermittent outpatient infusion
  • for scheduled repetitive use
  • to improve renal function
  • to enhance diuresis

References

• Hodgson, Barbara B., and Kizior, Robert J. Saunders Nursing Drug Handbook 2006. St. Louis, MO: Elsevier, Saunders, 2006.
• Science or Fiction: Use of Nesiritide as a First-Line Agent? John A. Noviasky, Pharm.D., Michael Kelberman, M.D., Karen M. Whalen, B.S., Roy Guharoy, Pharm.D., William Darko, Pharm.D.[2]

External links

• Natrecor.com